European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma

Journal of Clinical Oncology

Volumn 18, Issue 2, 2000, Pages 317-324

  Foran, James M ^a   Rohatiner, Ama Z S ^b   Cunningham, David ^b   Popescu, Razvan A ^b   Solal Celigny, Philippe ^b   Ghielmini, Michele ^b   Coiffier, Bertrand ^b   Johnson, Peter W M ^b   Gisselbrecht, Christian ^b   Reyes, Felix ^b   Radford, John A ^b   Bessell, Eric M ^b   Souleau, Bertrand ^b   Benzohra, Aziz ^b   Lister, T Andrew ^b  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOXORUBICIN; MITOXANTRONE; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; B CELL LYMPHOMA; BLOOD TOXICITY; CLINICAL TRIAL; FEVER; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INFECTION; LETHARGY; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SPLEEN RUPTURE; VOMITING;

EID: 0033968522     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.2000.18.2.317     Document Type: Article

References (36)

1. Ehrlich P: On immunity with special reference to cell life. Proc R Soc Lond [Biol] 66:424-448, 1990
2. Köhler G, Milstein C: Continuous cultures of fused cells secreting monoclonal antibody of predefined specificity. Nature 256:495-497, 1975
3. Grossbard ML, Press OW, Appelbaum FR, et al: Monoclonal antibody-based therapies of leukemia and lymphoma. Blood 80:863-878, 1992
4. Reff ME, Carner K, Chambers KS, et al: Depletion of B-cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435-445, 1994
5. Riechmann L, Clark M, Waldmann H, et al: Reshaping human antibodies for therapy. Nature 332:323-327, 1988
6. Zhou LJ, Tedder TF: CD20 workshop panel report, in Schlossman SF, Boumsell L, Gilks W, et al (eds): Leucocyte Typing V: White Cell Differentiation Antigens-Proceedings of the Fifth International Workshop and Conference, Boston, MA, 3-7 November 1993. Oxford, United Kingdom, Oxford University Press, 1995, pp 511-514
7. Tedder TF, Engel P: CD20: A regulator of cell-cycle progression of B lymphocytes. Immunol Today 15:450-454, 1994
8. Shan D, Ledbetter JA, Press OW: Apoptosis of malignant B cells by ligation of CD20 with monoclonal antibodies. Blood 91:1644-1652, 1998
9. Maloney DG, Liles TM, Czerwinski DK, et al: Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84:2457-2466, 1994
10. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al: IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 15:3266-3274, 1997
11. Maloney DG, Grillo-Lopez AJ, White CA, et al: IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90:2188-2195, 1997
12. McLaughlin P, Grillo-Lopez AJ, Link BK, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998
13. Stansfeld AG, Diebold J, Noel H, et al: Updated Kiel classification for lymphomas. Lancet 1:292-293, 1988 (letter)
14. Harris NL, Jaffe ES, Stein H, et al: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994
15. The non-Hodgkin's lymphoma classification project: A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 89:3909-3918, 1997
16. Dimopoulos MA, Alexanian R: Waldenstrom's macroglobulinemia. Blood 83:1452-1459, 1994
17. Berger F, Felman P, Sonet A, et al: Nonfollicular small B-cell lymphomas: An heterogeneous group of patients with distinct clinical features and outcome. Blood 83:2829-2835, 1994
18. Brittinger G, Bartels H, Common H, et al: Clinical and prognostic relevance of the Kiel classification of non-Hodgkin's lymphomas: Results of a prospective multicentre study by the Kiel lymphoma study group. Hematol Oncol 2:269-306, 1984
19. Norton AJ, Matthews J, Pappa V, et al: Mantle cell lymphoma: Natural history defined in a serially biopsied population over a 20 year period. Ann Oncol 6:249-256, 1995
20. Papamichael D, Norton AJ, Foran JM, et al: Immunocytoma: A retrospective analysis form St. Bartholomew's Hospital, 1972-1996. J Clin Oncol 17:2847-2853, 1999
21. Richards MA, Hall PA, Gregory WM, et al: Lymphoplasmacytoid and small cell centrocytic non-Hodgkin's lymphoma: A retrospective analysis from St. Bartholomew's Hospital 1972-1986. Hematol Oncol 7:19-35, 1989
22. Rituximab (IDEC-C2B8) [investigational drug brochure, ed 4]. IDEC Pharmaceuticals Corporation, San Diego, CA, 1997
23. Kaplan ES, Meier P: Non-parametric estimation from incomplete observation. Am Stat Assoc J 53:457-480, 1958
24. Meusers P, Engelhard M, Bartels H, et al: Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: Anthracycline does not improve the prognosis. Hematol Oncol 7:365-380, 1989
25. Hiddemann W, Brittinger G, Tiemann M, et al: Clinical characteristics and response to chemotherapy of mantle cell lymphomas: Results of a European survey. Proc Am Soc Hematol 88:674a, 1996 (abstr)
26. Stewart DA, Vose JM, Weisenberger DD, et al: The role of high-dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Ann Oncol 6:263-266, 1995
27. Ketterer N, Salles G, Espinouse D, et al: Intensive therapy with peripheral stem cell transplantation in 16 patients with mantle cell lymphoma. Ann Oncol 8:701-704, 1997
28. Freedman AS, Neuberg D, Gribben JG, et al: High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: No evidence for long-term remission. J Clin Oncol 16:13-18, 1998
29. Coiffier B, Haioun C, Ketterer N, et al: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicentre phase II study. Blood 92:1927-1932, 1998
30. Berinstein NL, Grillo-Lopez AJ, White CA, et al: Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 9:995-1001, 1998
31. Molica S, Levato D, Dattilo A, et al: Clinico-prognostic relevance of quantitative immunophenotyping in B-cell chronic lymphocytic leukemia with emphasis on the expression of CD20 antigen and surface immunoglobulins. Eur J Hematol 60:47-52, 1998
32. Piro L, White CA, Grillo-Lopez AJ, et al: Rituxan (rituximab; IDEC-C2B8): Interim analysis of a phase II study of once weekly times 8 dosing in patients with relapsed low-grade or follicular non-Hodgkin's lymphoma. Proc Am Soc Hematol 90:510a, 1997 (abstr) (suppl 1)
33. Oinonen R, Franssila K, Elonene E: Spontaneous splenic rupture in two patients with a blastoid variant of mantle cell lymphoma. Ann Hematol 74:33-35, 1997
34. Winkler U, Jensen M, Manzke O, et al: Severe side effects in patients with B-cell chronic lymphocytic leukemia and leukocytosis treated with the monoclonal anti-CD20 antibody rituximab. Proc Am Soc Hematol 92:285b, 1998 (abstr) (suppl 1)
35. Nguyen D, Amess J, Doughty H, et al: IDEC-C2B8 anti-CD20 immunotherapy in patients with non-Hodgkin's lymphoma: Hematological effects in the bone marrow and peripheral blood. Proc Am Soc Hematol 90:511a, 1997 (abstr) (suppl 1)
36. Czuczman MS, Grillo-Lopez AJ, White CA, et al: Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17:268-276, 1999